false0001755237NONE00017552372026-11-132026-11-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

 

 

Korsana Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Massachusetts

001-38787

83-1895370

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

203 Crescent Street

Bldgs. #3/3A/4

Suite 503

 

Waltham, Massachusetts

 

02453

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 516-2325

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, no par value per share

 

KRSA

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 13, 2026, Korsana Biosciences, Inc. (the “Company”) held a special meeting of shareholders (the “Special Meeting”) exclusively online via live webcast. As of October 7, 2026, the record date for the Special Meeting, 45,541,358 shares of the Company’s common stock were issued, outstanding and entitled to vote. A total of 40,022,552 shares were present at the Special Meeting in person or represented by proxy, constituting a quorum.

At the Special Meeting, the Company’s shareholders voted on the two proposals described below, each of which is described in greater detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 15, 2026 (the “Proxy Statement”). Proposal Nos. 1 and 2 together comprise the “Redomestication Proposal.” The final voting results for each proposal are set forth below.

Proposal No. 1. Shareholders approved, pursuant to the Massachusetts Business Corporation Act, the redomestication of the Company from a corporation organized under the laws of the Commonwealth of Massachusetts to an exempted company incorporated under the laws of the Cayman Islands by domestication pursuant to Section 9.20 of the Massachusetts Business Corporation Act, as set forth in the plan of domestication attached as Annex A to the Proxy Statement, and adopted the resolutions of the Board of Directors approving the redomestication, attached as Annex E to the Proxy Statement (the “Domestication Proposal”). The voting results were as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

36,182,762

 

3,839,724

 

67

 

—

 

Proposal No. 2. Shareholders approved (i) pursuant to the Companies Act (As Revised) of the Cayman Islands, the redomestication of the Company from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and the resolutions of the Board of Directors approving the redomestication and (ii) as a special resolution for purposes of Cayman Islands law, the adoption of the memorandum and articles of association of the Company, substantially in the form attached as Annex B to the Proxy Statement (the “Continuation and Cayman Articles Proposal”). The voting results were as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

36,183,829

 

3,838,657

 

67

 

—

 

Proposal No. 3. In connection with the Special Meeting, the Company also solicited proxies with respect to a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Redomestication Proposal. As there were sufficient votes to approve each of the Domestication Proposal and the Continuation and Cayman Articles Proposal, an adjournment of the Special Meeting was determined not to be necessary.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KORSANA BIOSCIENCES, INC.

 

 

 

 

Date:

November 19, 2026

By:

/s/ Mark Vignola

 

 

 

Mark Vignola, Ph.D.
Chief Financial Officer